HUE055269T2 - Anti-HER2 ellenanyag és konjugátum - Google Patents

Anti-HER2 ellenanyag és konjugátum

Info

Publication number
HUE055269T2
HUE055269T2 HUE18204950A HUE18204950A HUE055269T2 HU E055269 T2 HUE055269 T2 HU E055269T2 HU E18204950 A HUE18204950 A HU E18204950A HU E18204950 A HUE18204950 A HU E18204950A HU E055269 T2 HUE055269 T2 HU E055269T2
Authority
HU
Hungary
Prior art keywords
conjugate
her2 antibody
her2
antibody
Prior art date
Application number
HUE18204950A
Other languages
English (en)
Inventor
Jianmin Fang
Changjiang Huang
Jing Jiang
Xuejing Yao
Hongwen Li
Qiaoyu Xu
Zhuanglin Li
Original Assignee
Remegen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Co Ltd filed Critical Remegen Co Ltd
Publication of HUE055269T2 publication Critical patent/HUE055269T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HUE18204950A 2013-11-19 2014-11-18 Anti-HER2 ellenanyag és konjugátum HUE055269T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310586326 2013-11-19

Publications (1)

Publication Number Publication Date
HUE055269T2 true HUE055269T2 (hu) 2021-11-29

Family

ID=53178934

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18204950A HUE055269T2 (hu) 2013-11-19 2014-11-18 Anti-HER2 ellenanyag és konjugátum

Country Status (19)

Country Link
US (1) US10087260B2 (hu)
EP (2) EP3072907B1 (hu)
JP (2) JP6326137B2 (hu)
KR (3) KR101854443B1 (hu)
CN (3) CN105008398B (hu)
AU (1) AU2014352475B2 (hu)
CA (1) CA2919359C (hu)
CY (1) CY1124651T1 (hu)
DK (2) DK3072907T3 (hu)
ES (1) ES2879799T3 (hu)
HR (1) HRP20211023T1 (hu)
HU (1) HUE055269T2 (hu)
LT (1) LT3480215T (hu)
PL (1) PL3480215T3 (hu)
PT (1) PT3480215T (hu)
RS (1) RS62157B1 (hu)
RU (1) RU2656161C1 (hu)
SI (1) SI3480215T1 (hu)
WO (1) WO2015074528A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087260B2 (en) * 2013-11-19 2018-10-02 Remegen, Ltd. Anti-HER2 antibody and conjugate thereof
KR101796277B1 (ko) 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3845252A4 (en) 2018-08-29 2022-06-15 RemeGen, Ltd. USE OF AN ANTI-HER2-DRUG ANTIBODY CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA
SG11202105135QA (en) 2018-12-17 2021-07-29 Remegen Co A linker for antibody-drug conjugates and its use
CN109498816A (zh) * 2019-01-07 2019-03-22 合肥瀚科迈博生物技术有限公司 一种抗体偶联药物的制备方法
EP3842460A1 (en) * 2019-03-01 2021-06-30 RemeGen Co., Ltd. Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof
DK3811979T3 (da) * 2019-03-26 2024-01-02 Remegen Co Ltd Farmaceutisk præparat med anti-HER2-antistoflægemiddelkonjugat
CN111939267A (zh) * 2019-05-17 2020-11-17 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
CA3159770A1 (en) 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
AU2021210412A1 (en) * 2020-01-23 2022-08-18 Bioatla, Inc. Conditionally active anti-HER2 antibodies, antibody fragments their immunoconjugates and uses thereof
CN112353947A (zh) * 2020-11-23 2021-02-12 荣昌生物制药(烟台)股份有限公司 一种含二甲双胍和抗体药物偶联物的药物组合物及其应用
CN112402616A (zh) * 2020-11-23 2021-02-26 荣昌生物制药(烟台)股份有限公司 一种含环丙沙星和抗体药物偶联物的药物组合物及其应用
CN114796519A (zh) * 2021-01-27 2022-07-29 南开大学 一种蛋白质偶联小分子药物的制备和应用
IL305095A (en) * 2021-02-18 2023-10-01 Remegen Co Ltd Use of a HER2-targeted antibody-drug conjugate in the treatment of specific breast cancer
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN114736300B (zh) * 2022-06-09 2022-08-19 苏州百道医疗科技有限公司 一种抗her2重组兔单克隆抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2283866T3 (en) 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN109045307A (zh) 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
ES2521140T3 (es) 2004-07-22 2014-11-12 Genentech, Inc. Composición de anticuerpos de HER2
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CN101143902B (zh) 2007-05-18 2010-06-02 中国医学科学院医药生物技术研究所 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM)
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
DK2260111T3 (en) 2008-03-14 2015-09-14 Genentech Inc Genetic variations that are associated with drug resistance
EP2644204B1 (en) * 2008-03-18 2017-04-19 Genentech, Inc. Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
EP2327177B1 (en) * 2008-09-19 2017-11-08 Telefonaktiebolaget LM Ericsson (publ) Protection mechanism for a communications network
CN102030827B (zh) 2009-09-25 2014-09-24 上海抗体药物国家工程研究中心有限公司 一种高亲和力的抗her2单克隆抗体
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
CN102167742B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2542589A4 (en) * 2010-03-04 2013-08-07 Symphogen As ANTIBODIES AND COMPOSITIONS ANTI-HER2
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
JP6082344B2 (ja) * 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
US9193791B2 (en) * 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
CN104428318B (zh) 2012-05-02 2018-09-25 西福根有限公司 人源化泛her抗体组合物
US10087260B2 (en) * 2013-11-19 2018-10-02 Remegen, Ltd. Anti-HER2 antibody and conjugate thereof

Also Published As

Publication number Publication date
BR112016002752A2 (pt) 2017-11-21
CN109320612A (zh) 2019-02-12
BR112016002752A8 (pt) 2023-02-28
PL3480215T3 (pl) 2021-12-13
AU2014352475A1 (en) 2016-02-18
DK3072907T3 (en) 2019-04-01
CA2919359A1 (en) 2015-05-28
DK3480215T3 (da) 2021-07-05
CN105008398B (zh) 2018-10-16
KR101993136B1 (ko) 2019-06-26
CY1124651T1 (el) 2022-07-22
KR101854443B1 (ko) 2018-06-15
JP6326137B2 (ja) 2018-05-16
JP6728264B2 (ja) 2020-07-22
CN110240655B (zh) 2023-05-16
KR20180050423A (ko) 2018-05-14
EP3480215B8 (en) 2021-07-28
WO2015074528A1 (zh) 2015-05-28
AU2014352475B2 (en) 2017-08-17
RU2016106339A (ru) 2017-12-25
EP3480215A1 (en) 2019-05-08
KR101936697B1 (ko) 2019-01-10
CN105008398A (zh) 2015-10-28
EP3072907A1 (en) 2016-09-28
LT3480215T (lt) 2021-08-25
JP2016528902A (ja) 2016-09-23
JP2018138034A (ja) 2018-09-06
DK3480215T5 (da) 2021-08-16
RS62157B1 (sr) 2021-08-31
PT3480215T (pt) 2021-07-05
RU2656161C1 (ru) 2018-05-31
EP3072907B1 (en) 2019-02-20
EP3480215B1 (en) 2021-06-23
HRP20211023T1 (hr) 2021-09-17
CN109320612B (zh) 2020-10-27
SI3480215T1 (sl) 2021-12-31
KR20160065972A (ko) 2016-06-09
US20160304621A1 (en) 2016-10-20
KR20190002716A (ko) 2019-01-08
EP3072907A4 (en) 2017-06-14
ES2879799T3 (es) 2021-11-23
CN110240655A (zh) 2019-09-17
US10087260B2 (en) 2018-10-02
CA2919359C (en) 2019-01-15

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
HK1232243A1 (zh) 抗- 抗體及其用途
HK1217956A1 (zh) 新的抗體綴合物及其用途
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
PL3480215T3 (pl) Przeciwciało anty-HER2 i jego koniugat
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
IL240517A0 (en) Antibodies against b7–h4 and immunoconjugates
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
HK1223950A1 (zh) 單克隆 抗體及其用途